Helix Biopharma Corp., of Toronto, said it received private placement subscription agreements for units totaling aggregate proceeds of about C$1.82 million (US$1.4 million) and had closed on C$1.58 million. Terms called for the purchase of units at $1.20 each, with each unit consisting of one common share and one common share purchase warrant. Net proceeds are expected to be used for working capital and R&D activities.